Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMoltó, José-
dc.contributor.authorValle, Marta-
dc.contributor.authorSantos, José Ramón-
dc.contributor.authorMiranda, Cristina-
dc.contributor.authorCedeño, Samandhy-
dc.contributor.authorNegredo, Eugènia-
dc.contributor.authorYritia, Mercedes-
dc.contributor.authorVidela, Sebas-
dc.contributor.authorClotet i Sala, Bonaventura-
dc.description.abstractRitonavir-related adverse events have been reported in patients taking tipranavir/ritonavir at the licensed dosage of 500/200 mg twice daily (bid). The aim of this open-label, prospective, single-arm pilot study was to evaluate the efficacy and safety of a ritonavir dose reduction to 100 mg bid guided by the tipranavir virtual inhibitory quotient (vIQ) in HIV-infected patients receiving tipranavir/ritonavir 500/200 mg bid whose viral load was <50 copies/ml and whose tipranavir vIQ was >60. Viral load, blood chemistry, and tipranavir and ritonavir trough concentrations (C(trough)) in plasma were determined at baseline and up to 48 weeks. If the tipranavir vIQ fell to <40, the ritonavir dose was increased to 200 mg bid. The primary endpoint was the percentage of treatment failure after 48 weeks. Eleven patients were enrolled. At baseline, the median (IQR) CD4+ T-cell count and vIQ were 380 (231-520) cells/mm(3) and 233.4 (73.8-584.8), respectively. Ten patients (90.9%) maintained a viral load <50 copies/ml at week 48. Geometric mean (95% confidence interval) tipranavir C(trough) decreased from 24.7 (12.9-47.5) mg/l at baseline to 13.6 (7.1-26.2) mg/l at week 48 (p = 0.194), but the ritonavir dose had to be raised in only one patient. Median triglycerides and ALT concentrations decreased from 177.2 (132.9-292.4) mg/dl and 59 (23-128) IU/l at baseline to 158.0 (131.0-186.0) mg/dl and 28 (20-71) IU/l at week 48 (p = 0.047, p = 0.041), respectively. As a conclusion, ritonavir-dose reduction to 100 mg bid as a treatment-simplification strategy guided by the tipranavir vIQ in patients receiving salvage therapy with tipranavir/ritonavir 500/200 mg bid seems to be safe enough to be tested in adequately powered clinical trials.-
dc.format.extent6 p.-
dc.publisherMary Ann Liebert-
dc.relation.isformatofReproducció del document publicat a:
dc.relation.ispartofAids Research and Human Retroviruses, 2010, vol. 26, num. 11, p. 1191-1196-
dc.rights(c) Mary Ann Liebert, 2010-
dc.subject.classificationVIH (Virus)-
dc.subject.classificationAdministració de medicaments-
dc.subject.classificationEfectes secundaris dels medicaments-
dc.subject.otherHIV (Viruses)-
dc.subject.otherAdministration of drugs-
dc.subject.otherDrug side effects-
dc.titleEfficacy and safety of ritonavir dose reduction based on the tipranavir inhibitory quotient in HIV-infected patients on salvage antiretroviral therapy with tipranavir/ritonavir-
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)

Files in This Item:
File Description SizeFormat 
700134.pdf93.52 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.